Page 1 of 120
NR 566 MIDTERM EXAM — CHAMBERLAIN ADVANCED
PHARMACOLOGY FOR CARE OF THE FAMILY UPDATED EXAM
COMPREHENSIVE QUESTIONS AND CORRECT ANSWERS LATEST EDITION
2026
NR 566 Midterm Exam — Chamberlain Advanced Pharmacology for Care of the Family: 300
Practice Questions with Rationales
Summarized 10-Point Exam Coverage
Based on the Chamberlain NR 566 course structure and the midterm exam blueprint (Weeks 1–
4):
1. Pharmacokinetics & Pharmacodynamics — absorption, distribution, metabolism,
excretion, receptor theory, and therapeutic monitoring.
2. Autonomic Nervous System Drugs — cholinergic, anticholinergic, adrenergic, and
adrenergic-blocking agents.
3. Pharmacotherapy for Fungal Infections — azoles, polyenes, echinocandins, and topical
antifungals.
4. Pharmacotherapy for Viral Infections — antivirals for influenza, herpes, HIV, and
hepatitis.
5. Pharmacotherapy for Bacterial Infections — penicillins, cephalosporins, macrolides,
fluoroquinolones, and antibiotic stewardship.
6. Pharmacotherapy for Gender-Related Health — contraception, hormone replacement,
and gender-affirming care.
7. Pharmacotherapy for Urinary Conditions — UTIs, BPH, overactive bladder, and
interstitial cystitis.
8. Older Adult Considerations — polypharmacy, Beers Criteria, and age-related
pharmacokinetic changes.
1|Page
,Page 2 of 120
9. Legal & Ethical Prescribing — DEA regulations, controlled substances, and scope of
practice.
10. NGN Clinical Judgment — recognizing cues, prioritizing hypotheses, and evaluating
therapeutic outcomes.
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–40)
Q1. A nurse practitioner is reviewing the pharmacokinetic profile of a new medication. Which
process describes the movement of a drug from its site of administration into the systemic
circulation?
A) Distribution
B) Absorption
C) Metabolism
D) Excretion
Correct Answer: B) Absorption
Rationale: Absorption is the movement of a drug from its site of administration into the
systemic circulation. Oral medications must dissolve and cross gastrointestinal membranes
before entering the bloodstream. Distribution occurs after systemic absorption, while
metabolism and excretion contribute to elimination.
Q2. A patient with cirrhosis is prescribed a medication that undergoes extensive first-pass
metabolism. The nurse practitioner should anticipate which alteration in drug response?
A) Decreased drug effect due to enhanced metabolism
B) Increased drug effect due to reduced first-pass metabolism
C) No change in drug effect
D) Increased renal excretion of the drug
2|Page
,Page 3 of 120
Correct Answer: B) Increased drug effect due to reduced first-pass metabolism
Rationale: In cirrhosis, hepatic function is impaired, reducing first-pass metabolism and
increasing the bioavailability of drugs that normally undergo extensive hepatic extraction. This
can lead to elevated plasma concentrations and enhanced drug effects, potentially increasing
the risk of toxicity.
Q3. Which pharmacokinetic parameter describes the proportion of an administered drug dose
that reaches systemic circulation unchanged?
A) Half-life
B) Clearance
C) Bioavailability
D) Volume of distribution
Correct Answer: C) Bioavailability
Rationale: Bioavailability represents the fraction of an administered dose that reaches systemic
circulation in active form. Intravenous administration has essentially complete bioavailability,
whereas oral administration may have reduced bioavailability because of incomplete absorption
and first-pass metabolism.
Q4. A medication with a narrow therapeutic index requires particular attention to which
principle?
A) Minimal monitoring is necessary
B) Small changes in concentration may cause toxicity or treatment failure
C) The medication can be given at any dose
D) Therapeutic drug monitoring is never useful
Correct Answer: B) Small changes in concentration may cause toxicity or treatment failure
Rationale: A narrow therapeutic index means that the effective concentration is relatively close
3|Page
, Page 4 of 120
to the toxic concentration. Drugs in this category may require serum-level monitoring, careful
dose adjustment, and assessment for drug interactions.
Q5. Which organ is primarily responsible for metabolism of many medications?
A) Liver
B) Spleen
C) Pancreas
D) Thyroid
Correct Answer: A) Liver
Rationale: The liver contains numerous metabolic enzymes, including cytochrome P450
enzymes, that transform many medications into metabolites. Hepatic impairment can alter drug
exposure and may require dose or medication selection adjustments.
Q6. What is the principal purpose of a loading dose?
A) To permanently increase renal clearance
B) To rapidly achieve a desired therapeutic concentration
C) To eliminate adverse effects
D) To prevent absorption
Correct Answer: B) To rapidly achieve a desired therapeutic concentration
Rationale: A loading dose is used when rapid achievement of therapeutic drug concentrations is
clinically desirable. The appropriate loading dose depends substantially on the medication's
volume of distribution and the target concentration.
Q7. Which statement best describes pharmacodynamics?
4|Page
NR 566 MIDTERM EXAM — CHAMBERLAIN ADVANCED
PHARMACOLOGY FOR CARE OF THE FAMILY UPDATED EXAM
COMPREHENSIVE QUESTIONS AND CORRECT ANSWERS LATEST EDITION
2026
NR 566 Midterm Exam — Chamberlain Advanced Pharmacology for Care of the Family: 300
Practice Questions with Rationales
Summarized 10-Point Exam Coverage
Based on the Chamberlain NR 566 course structure and the midterm exam blueprint (Weeks 1–
4):
1. Pharmacokinetics & Pharmacodynamics — absorption, distribution, metabolism,
excretion, receptor theory, and therapeutic monitoring.
2. Autonomic Nervous System Drugs — cholinergic, anticholinergic, adrenergic, and
adrenergic-blocking agents.
3. Pharmacotherapy for Fungal Infections — azoles, polyenes, echinocandins, and topical
antifungals.
4. Pharmacotherapy for Viral Infections — antivirals for influenza, herpes, HIV, and
hepatitis.
5. Pharmacotherapy for Bacterial Infections — penicillins, cephalosporins, macrolides,
fluoroquinolones, and antibiotic stewardship.
6. Pharmacotherapy for Gender-Related Health — contraception, hormone replacement,
and gender-affirming care.
7. Pharmacotherapy for Urinary Conditions — UTIs, BPH, overactive bladder, and
interstitial cystitis.
8. Older Adult Considerations — polypharmacy, Beers Criteria, and age-related
pharmacokinetic changes.
1|Page
,Page 2 of 120
9. Legal & Ethical Prescribing — DEA regulations, controlled substances, and scope of
practice.
10. NGN Clinical Judgment — recognizing cues, prioritizing hypotheses, and evaluating
therapeutic outcomes.
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–40)
Q1. A nurse practitioner is reviewing the pharmacokinetic profile of a new medication. Which
process describes the movement of a drug from its site of administration into the systemic
circulation?
A) Distribution
B) Absorption
C) Metabolism
D) Excretion
Correct Answer: B) Absorption
Rationale: Absorption is the movement of a drug from its site of administration into the
systemic circulation. Oral medications must dissolve and cross gastrointestinal membranes
before entering the bloodstream. Distribution occurs after systemic absorption, while
metabolism and excretion contribute to elimination.
Q2. A patient with cirrhosis is prescribed a medication that undergoes extensive first-pass
metabolism. The nurse practitioner should anticipate which alteration in drug response?
A) Decreased drug effect due to enhanced metabolism
B) Increased drug effect due to reduced first-pass metabolism
C) No change in drug effect
D) Increased renal excretion of the drug
2|Page
,Page 3 of 120
Correct Answer: B) Increased drug effect due to reduced first-pass metabolism
Rationale: In cirrhosis, hepatic function is impaired, reducing first-pass metabolism and
increasing the bioavailability of drugs that normally undergo extensive hepatic extraction. This
can lead to elevated plasma concentrations and enhanced drug effects, potentially increasing
the risk of toxicity.
Q3. Which pharmacokinetic parameter describes the proportion of an administered drug dose
that reaches systemic circulation unchanged?
A) Half-life
B) Clearance
C) Bioavailability
D) Volume of distribution
Correct Answer: C) Bioavailability
Rationale: Bioavailability represents the fraction of an administered dose that reaches systemic
circulation in active form. Intravenous administration has essentially complete bioavailability,
whereas oral administration may have reduced bioavailability because of incomplete absorption
and first-pass metabolism.
Q4. A medication with a narrow therapeutic index requires particular attention to which
principle?
A) Minimal monitoring is necessary
B) Small changes in concentration may cause toxicity or treatment failure
C) The medication can be given at any dose
D) Therapeutic drug monitoring is never useful
Correct Answer: B) Small changes in concentration may cause toxicity or treatment failure
Rationale: A narrow therapeutic index means that the effective concentration is relatively close
3|Page
, Page 4 of 120
to the toxic concentration. Drugs in this category may require serum-level monitoring, careful
dose adjustment, and assessment for drug interactions.
Q5. Which organ is primarily responsible for metabolism of many medications?
A) Liver
B) Spleen
C) Pancreas
D) Thyroid
Correct Answer: A) Liver
Rationale: The liver contains numerous metabolic enzymes, including cytochrome P450
enzymes, that transform many medications into metabolites. Hepatic impairment can alter drug
exposure and may require dose or medication selection adjustments.
Q6. What is the principal purpose of a loading dose?
A) To permanently increase renal clearance
B) To rapidly achieve a desired therapeutic concentration
C) To eliminate adverse effects
D) To prevent absorption
Correct Answer: B) To rapidly achieve a desired therapeutic concentration
Rationale: A loading dose is used when rapid achievement of therapeutic drug concentrations is
clinically desirable. The appropriate loading dose depends substantially on the medication's
volume of distribution and the target concentration.
Q7. Which statement best describes pharmacodynamics?
4|Page
